ROCKVILLE, Md., July 23,
2024 /PRNewswire/ -- Emmes Group, a leading
specialty tech-enabled global contract research organization (CRO),
today announced a multi-year strategic partnership with Miimansa
AI. A critical pillar of the partnership, aimed at revolutionizing
clinical research at Emmes, is the acquisition of Miimansa's
Clinical Entity Modeling tools based on advanced large language
modeling (LLM) techniques and generative AI.
Artificial intelligence (AI) promises to transform all aspects
of healthcare including clinical research. Emmes Group is rapidly
maturing its technology platform, Veridix AI, and Miimansa's
Clinical Entity Modeling technology will serve as a critical
building block to accelerate the development of state-of-the-art
automated text processing solutions tailored for clinical
research.
The partnership will focus on creating capabilities for quickly
and accurately processing vast amounts of clinical data and
enabling text to text transformations such as protocol authoring
and medical writing, reducing the time and cost associated with
manual data handling and analysis.
"We are excited to partner with Miimansa AI to bring
cutting-edge AI technology to the forefront of clinical research,"
said Sastry Chilukuri, CEO of Emmes
Group. "The clinical entity modeling tools acquired through our
partnership will accelerate development and adoption of Emmes
Groups' Gen AI platform, named Concord, to drive faster, better and
more efficient clinical trials."
Dr. Vibhu Agarwal, founder and
CEO of Miimansa AI, added, "Teaming up with Emmes Group is a
significant milestone for us. Their expertise and comprehensive
clinical trial data offer a unique opportunity to apply our
advanced AI techniques in real-world settings. Together, we aim to
transform the landscape of clinical research, making it faster,
more affordable, and ultimately more successful in delivering safe
and effective treatments."
About Emmes Group:
Emmes Group is a privately held contract research organization
(CRO), wholly owned by New Mountain Capital
(https://www.newmountaincapital.com). Emmes Group was founded as
Emmes more than 47 years ago, becoming one of the primary clinical
research providers to the US government before expanding into
public-private partnerships and commercial biopharma. Emmes Group
has built industry leading capabilities in cell and gene therapy,
vaccines and infectious diseases, ophthalmology, rare diseases, and
neuroscience. Today, the company is transforming the future of
clinical research, by creating the industry's first native digital
and AI based CRO optimized to deliver programs faster, better, and
more efficiently. Where human intelligence meets artificial
intelligence.
About Miimansa AI
Miimansa AI is a health tech startup
at the forefront of AI and machine learning applications in life
sciences and healthcare. The company is led by former faculty and
alumni from IIT Kanpur and Stanford
University. Specializing in clinical data management and
biomedical research, Miimansa AI develops innovative solutions that
leverage large language models to automate and enhance various
aspects of clinical research.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/emmes-group-partners-with-miimansa-ai-to-accelerate-adoption-of-generative-ai-in-clinical-research-302203271.html
SOURCE EMMES